Physician profile
David A Mack
NPI 1396966818
$12,224.07
in general payments reported to CMS, 2019-2025
43 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $161 · 2021: $2,514 · 2022: $2,960 · 2023: $1,620 · 2024: $1,497 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,487 · Consulting Fee: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,487.07 |
| Consulting Fee | $1,312.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $2,041.01 | 2021-2022 | |
| Glaxosmithkline, LLC. | $1,882.20 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,332.92 | 2021-2025 | Ninlaro |
| Pfizer INC. | $919.00 | 2019-2025 | |
| Genentech USA, INC. | $712.37 | 2019-2025 | Polivy, Phesgo, Lunsumio |
| Celgene Corporation | $691.91 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Daiichi Sankyo INC. | $416.90 | 2022-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals Lp | $375.55 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $368.44 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $365.94 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Gilead Sciences, INC. | $337.47 | 2019-2025 | Trodelvy |
| Array Biopharma INC | $277.10 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $267.75 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Janssen Biotech, INC. | $205.70 | 2019-2025 | Rybrevant, Darzalex, Imbruvica |
| Beigene USA, INC. | $192.47 | 2023-2025 | Brukinsa, Tevimbra |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $181.78 | 2019-2025 | |
| Emd Serono, INC. | $162.10 | 2019-2024 | Bavencio |
| Novartis Pharmaceuticals Corporation | $159.41 | 2019-2023 | |
| Exelixis INC. | $154.89 | 2019-2024 | Cabometyx |
| Sobi, INC | $133.77 | 2022-2025 | |
| Kite Pharma, INC. | $133.40 | 2022-2023 | Yescarta |
| Incyte Corporation | $107.43 | 2021-2025 | Monjuvi |
| Genmab U.S., INC. | $101.92 | 2023-2025 | Epkinly |
| Abbvie INC. | $77.29 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $70.75 | 2021-2023 | Libtayo |
| Astellas Pharma US INC | $59.64 | 2024-2025 | Vyloy, Padcev |
| Menarini Silicon Biosystems, INC. | $59.03 | 2023-2025 | Cellsearch |
| Puma Biotechnology, INC. | $53.21 | 2023 | |
| Foundation Medicine, INC. | $49.31 | 2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Genzyme Corporation | $47.28 | 2019-2023 | |
| Beone Medicines USA, INC. | $40.55 | 2025 | Brukinsa |
| Kestra Medical Technology Services, INC. | $38.59 | 2024 | Assure Wcd |
| Deciphera Pharmaceuticals INC. | $36.87 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $28.24 | 2024 | Givlaari |
| Eusa Pharma (US) LLC | $18.53 | 2022 | |
| Mirati Therapeutics, INC. | $17.68 | 2024 | Krazati |
| Coherus Oncology, INC. | $16.73 | 2024 | |
| Kyowa Kirin, INC. | $16.24 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.49 | 2023 | Gilotrif |
| Azurity Pharmaceuticals, INC. | $15.05 | 2025 | Vivimusta, Danziten |
| Jazz Pharmaceuticals INC. | $13.79 | 2022 | |
| Tersera Therapeutics LLC | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.